Cost-cutting impacts Positron results
PET developer Positron’s year of hibernation was reflected in the company’s 1998 financial results (end-December), which were released this month. The Houston company sold no systems in 1998, compared with one sale of $1.1 million the year
PET developer Positrons year of hibernation was reflected in the companys 1998 financial results (end-December), which were released this month. The Houston company sold no systems in 1998, compared with one sale of $1.1 million the year before. The vendor reported revenues of $2 million last year, thanks to service and fee-per-scan revenues, while in 1997 Positron had sales of $3.5 million. Positron did have some good news for the year, however. Thanks to cost-cutting efforts, its net loss decreased to $724,000, an improvement on last years loss of $4.5 million.
Yet despite modest results for 1998, Positron may be gaining strength. In April 1998, the company was unsure it could continue as a going concern; in May, it signed an agreement with South San Francisco CT developer Imatron, in which Imatron acquired a majority stake in Positron and began feeding the company working capital (SCAN 5/13/98). Imatrons purchase was finalized early this year, and since then Imatron has been negotiating with third-party investors to help resuscitate the company (SCAN 2/3/99).
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
